Clinical trial
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage…
NCT00017303 · Cytran, Industry · Unknown status
Key facts
| NCT number | NCT00017303 |
|---|---|
| Title | Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer |
| Official title | A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy |
| Lead sponsor | Cytran, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug, Procedure |
| Interventions | carboplatin, oglufanide disodium, paclitaxel, conventional surgery |
| Start date | Jan 1, 2001 |
| First posted | Feb 27, 2004 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: